Related Experiment Video
Updated: Sep 1, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
Karen L R Paiva1,2, Marina A Radicchi1,3, Sônia N Báo1
1Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, DF, Brazil.
Abstract:
Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the activity of a solid lipid nanoparticle containing docetaxel (SLN-DTX), a drug already used in conventional therapies, was evaluated in a cell line (MDA-MB-231) of one of the most aggressive types of breast cancer with the worst prognosis, triple-negative breast cancer. Viability tests indicated that SLN-DTX has a greater dependence on the treatment dose when compared to the free drug, which indicates a more controlled release of the drug, and both reduced viability by around 50% at a concentration of 1 µg/mL after 72 h. Transmission electron microscopy (TEM) and confocal and light microscopy analyses indicated that after treatment the cells enter a mitotic catastrophe, characteristic of antimitotic drugs that usually make cells progress to death or senescence. Cells treated with both DTX and SLN-DTX showed significant inhibition of mobility, 73.6% and 66.5% when treated with SLN-DTX and DTX, respectively, compared to the 11.4% of the control after 72 h, characteristics that are very relevant in tumor development and progression. SLN-DTX demonstrated its great potential as a nanocarrier by maintaining and improving the drug's action in the MDA-MB-231 cell line.
Insights
Solid lipid nanoparticles (SLN) loaded with docetaxel (DTX) show improved anti-cancer effects against triple-negative breast cancer cells. This novel nanocarrier maintains and enhances docetaxel
Area of Science:
- Nanomedicine
- Oncology
- Drug Delivery
Background:
- Cancer remains a leading cause of mortality worldwide, necessitating improved therapeutic strategies.
- Conventional chemotherapy faces challenges like poor solubility and adverse effects, impacting patient quality of life.
- Triple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis, highlighting the need for effective treatments.
Purpose of the Study:
- To evaluate the efficacy of solid lipid nanoparticles containing docetaxel (SLN-DTX) against the MDA-MB-231 TNBC cell line.
- To assess the drug release characteristics and cellular effects of SLN-DTX compared to free docetaxel (DTX).
Main Methods:
- Cell viability assays were performed on MDA-MB-231 cells treated with SLN-DTX and free DTX.
- Transmission electron microscopy (TEM) and confocal/light microscopy were used to analyze cellular responses.
- Cellular mobility was quantified after treatment with SLN-DTX and DTX.
Main Results:
- SLN-DTX demonstrated dose-dependent cytotoxicity, reducing cell viability by approximately 50% at 1 µg/mL after 72 hours.
- Microscopy revealed that SLN-DTX induced mitotic catastrophe in cancer cells, a precursor to cell death or senescence.
- Both SLN-DTX and DTX significantly inhibited cell mobility, with SLN-DTX showing a 66.5% reduction compared to 11.4% in controls.
Conclusions:
- Solid lipid nanoparticles effectively deliver docetaxel, maintaining and enhancing its anti-cancer activity in TNBC.
- SLN-DTX exhibits controlled drug release and induces significant anti-proliferative and anti-migratory effects.
- SLN-DTX shows potential as a promising nanocarrier for improving docetaxel-based cancer therapy.
